Terms: = Endocrine gland cancer AND HOXD13, SPD, 3239, P35453, HOX4I
55 results:
1. Systems pharmacodynamic model of combined gemcitabine and trabectedin in pancreatic cancer cells. Part I.Çô Effects on signal transduction pathways related to tumor growth.
Miao X; Shen S; Koch G; Wang X; Li J; Shen X; Qu J; Straubinger RM; Jusko WJ
J Pharm Sci; 2024 Jan; 113(1):214-227. PubMed ID: 38498417
[TBL] [Abstract] [Full Text] [Related]
2. Systems Pharmacodynamic Model of Combined Gemcitabine and Trabectedin in Pancreatic cancer Cells. Part II: Cell Cycle, DNA Damage Response, and Apoptosis Pathways.
Miao X; Koch G; Shen S; Wang X; Li J; Shen X; Qu J; Straubinger RM; Jusko WJ
J Pharm Sci; 2024 Jan; 113(1):235-245. PubMed ID: 37918792
[TBL] [Abstract] [Full Text] [Related]
3. Differential diagnosis between pancreatic solid pseudopapillary tumors and pancreatic neuroendocrine tumors based on contrast enhanced ultrasound imaging features.
Zhang Q; Qiu YJ; Yang DH; Lu XY; Chen S; Dong Y; Wang WP
Clin Hemorheol Microcirc; 2023; 85(4):421-431. PubMed ID: 37718786
[TBL] [Abstract] [Full Text] [Related]
4. Combination of pembrolizumab and pelareorep promotes anti-tumour immunity in advanced pancreatic adenocarcinoma (PDAC).
Mahalingam D; Chen S; Xie P; Loghmani H; Heineman T; Kalyan A; Kircher S; Helenowski IB; Mi X; Maurer V; Coffey M; Mulcahy M; Benson A; Zhang B
Br J Cancer; 2023 Sep; 129(5):782-790. PubMed ID: 37443348
[TBL] [Abstract] [Full Text] [Related]
5. Predicting the survival of patients with pancreatic neuroendocrine neoplasms using deep learning: A study based on Surveillance, Epidemiology, and End Results database.
Jiang C; Wang K; Yan L; Yao H; Shi H; Lin R
Cancer Med; 2023 Jun; 12(11):12413-12424. PubMed ID: 37165971
[TBL] [Abstract] [Full Text] [Related]
6. Standard pancreatoduodenectomy versus extended pancreatoduodenectomy with modified retroperitoneal nerve resection in patients with pancreatic head cancer: a multicenter randomized controlled trial.
Lin Q; Zheng S; Yu X; Chen M; Zhou Y; Zhou Q; Hu C; Gu J; Xu Z; Wang L; Liu Y; Liu Q; Wang M; Li G; Cheng H; Zhou D; Liu G; Fu Z; Long Y; Li Y; Wang W; Qin R; Li Z; Chen R
Cancer Commun (Lond); 2023 Feb; 43(2):257-275. PubMed ID: 36579790
[TBL] [Abstract] [Full Text] [Related]
7. Prokineticins as a Prognostic Biomarker for Low-Grade Gliomas: A Study Based on The cancer Genome Atlas Data.
Zhong J; Xiang D; Ma X
Biomed Res Int; 2022; 2022():2309339. PubMed ID: 35845958
[TBL] [Abstract] [Full Text] [Related]
8. Clinical and Prognostic Value of Antigen-Presenting Cells with PD-L1/PD-L2 Expression in Ovarian cancer Patients.
Pawłowska A; Kwiatkowska A; Suszczyk D; Chudzik A; Tarkowski R; Barczyński B; Kotarski J; Wertel I
Int J Mol Sci; 2021 Oct; 22(21):. PubMed ID: 34768993
[TBL] [Abstract] [Full Text] [Related]
9. The intestinal flora of patients with GHPA affects the growth and the expression of PD-L1 of tumor.
Nie D; Fang Q; Cheng J; Li B; Li M; Wang H; Li C; Gui S; Zhang Y; Zhao P
Cancer Immunol Immunother; 2022 May; 71(5):1233-1245. PubMed ID: 34647152
[TBL] [Abstract] [Full Text] [Related]
10. Clinical Effects of Microwave Ablation in the Treatment of Low-Risk Papillary Thyroid Microcarcinomas and Related Histopathological Changes.
Lu C; Li X; Chu X; Li R; Li J; Wang J; Wang Y; Xu Y; Chen G; Xu S; Liu C
Front Endocrinol (Lausanne); 2021; 12():751213. PubMed ID: 34603216
[TBL] [Abstract] [Full Text] [Related]
11. Neutralization of PD-L2 is Essential for Overcoming Immune Checkpoint Blockade Resistance in Ovarian cancer.
Miao YR; Thakkar KN; Qian J; Kariolis MS; Huang W; Nandagopal S; Yang TTC; Diep AN; Cherf GM; Xu Y; Moon EJ; Xiao Y; Alemany H; Li T; Yu W; Wei B; Rankin EB; Giaccia AJ
Clin Cancer Res; 2021 Aug; 27(15):4435-4448. PubMed ID: 34011561
[TBL] [Abstract] [Full Text] [Related]
12. Soluble forms of immune checkpoints in ovarian cancer.
Kovaleva OV; Belova TP; Kushlinsky DN; Korotkova EA; Podlesnaya PA; Gratchev AN; Zinoviev SV; Tereshkina IV; Sokolov NY; Kudlay DA; Kushlinskii NE
Klin Lab Diagn; 2021 Mar; 66(2):80-86. PubMed ID: 33734640
[TBL] [Abstract] [Full Text] [Related]
13. [Novel miRNAs as Potential Regulators of PD-1/PD-L1 Immune Checkpoint, and Prognostic Value of MIR9-1 and MIR124-2 Methylation in Ovarian cancer].
Kushlinskii NE; Loginov VI; Utkin DO; Filippova EA; Burdennyy AM; Korotkova EA; Pronina IV; Lukina SS; Smirnova AV; Gershtein ES; Braga EA
Mol Biol (Mosk); 2020; 54(6):990-996. PubMed ID: 33276362
[TBL] [Abstract] [Full Text] [Related]
14. PD-L1, PDK-1 and p-Akt are correlated in patients with papillary thyroid carcinoma.
Wang H; Zhang Z; Yan Z; Ma S
Adv Clin Exp Med; 2020 Jul; 29(7):785-792. PubMed ID: 32750756
[TBL] [Abstract] [Full Text] [Related]
15. Accumulation of blood-circulating PD-L1-expressing M-MDSCs and monocytes/macrophages in pretreatment ovarian cancer patients is associated with soluble PD-L1.
Okła K; Rajtak A; Czerwonka A; Bobiński M; Wawruszak A; Tarkowski R; Bednarek W; Szumiło J; Kotarski J
J Transl Med; 2020 Jun; 18(1):220. PubMed ID: 32487171
[TBL] [Abstract] [Full Text] [Related]
16. Detailed Analysis of Margin Positivity and the Site of Local Recurrence After Pancreaticoduodenectomy.
McIntyre CA; Zambirinis CP; Pulvirenti A; Chou JF; Gonen M; Balachandran VP; Kingham TP; D'Angelica MI; Brennan MF; Drebin JA; Jarnagin WR; Allen PJ
Ann Surg Oncol; 2021 Jan; 28(1):539-549. PubMed ID: 32451945
[TBL] [Abstract] [Full Text] [Related]
17. Total mesopancreas excision for periampullary malignancy: a single-center propensity score-matched comparison of long-term outcomes.
Quero G; Fiorillo C; Menghi R; Cina C; Galiandro F; Longo F; Sofo F; Rosa F; Tortorelli AP; Giustiniani MC; Inzani F; Alfieri S
Langenbecks Arch Surg; 2020 May; 405(3):303-312. PubMed ID: 32333095
[TBL] [Abstract] [Full Text] [Related]
18. Comparative Effectiveness of Pylorus-Preserving Versus Standard Pancreaticoduodenectomy in Clinical Practice.
Calderon E; Day RW; Stucky CC; Gray RJ; Pockaj BA; Chang YH; Wasif N
Pancreas; 2020 Apr; 49(4):568-573. PubMed ID: 32282771
[TBL] [Abstract] [Full Text] [Related]
19. Regional pancreatoduodenectomy versus standard pancreatoduodenectomy with portal vein resection for pancreatic ductal adenocarcinoma with portal vein invasion.
Oba A; Ito H; Ono Y; Sato T; Mise Y; Inoue Y; Takahashi Y; Saiura A
BJS Open; 2020 Jun; 4(3):438-448. PubMed ID: 32191395
[TBL] [Abstract] [Full Text] [Related]
20. Positive neck margin at frozen section analysis is a significant predictor of tumour recurrence and poor survival after pancreatodudenectomy for pancreatic cancer.
Crippa S; Guarneri G; Belfiori G; Partelli S; Pagnanelli M; Gasparini G; Balzano G; Lena MS; Rubini C; Doglioni C; Zamboni G; Falconi M
Eur J Surg Oncol; 2020 Aug; 46(8):1524-1531. PubMed ID: 32098733
[TBL] [Abstract] [Full Text] [Related]
[Next]
